BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18630479)

  • 21. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma.
    Turunen M; Talvensaari-Mattila A; Soini Y; Santala M
    Anticancer Res; 2009 Dec; 29(12):5185-9. PubMed ID: 20044634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic significance - a tissue microarray study of 129 cases.
    Chen SF; Yang SF; Li JW; Nieh PC; Lin SY; Fu E; Bai CY; Jin JS; Lin CY; Nieh S
    Histopathology; 2007 Aug; 51(2):173-83. PubMed ID: 17650213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fascin expression in progression and prognosis of hepatocellular carcinoma.
    Iguchi T; Aishima S; Umeda K; Sanefuji K; Fujita N; Sugimachi K; Gion T; Taketomi A; Maehara Y; Tsuneyoshi M
    J Surg Oncol; 2009 Dec; 100(7):575-9. PubMed ID: 19697358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
    Khouja MH; Baekelandt M; Nesland JM; Holm R
    Int J Gynecol Pathol; 2007 Oct; 26(4):418-25. PubMed ID: 17885492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic relevance of fascin expression in human gastric carcinoma.
    Hashimoto Y; Shimada Y; Kawamura J; Yamasaki S; Imamura M
    Oncology; 2004; 67(3-4):262-70. PubMed ID: 15557788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas.
    Gunal A; Onguru O; Safali M; Beyzadeoglu M
    Neuropathology; 2008 Aug; 28(4):382-6. PubMed ID: 18298442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer.
    Oh SY; Kim YB; Suh KW; Paek OJ; Moon HY
    J Surg Res; 2012 Jan; 172(1):102-8. PubMed ID: 20851411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters.
    Lin CK; Su HY; Tsai WC; Sheu LF; Jin JS
    Dis Markers; 2008; 25(1):17-26. PubMed ID: 18776588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.